BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a rare and aggressive endocrine tumor with highly undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in ATC. The objectives of this study were (i) to characterize CSCs from ex vivo ATC specimens by investigating the expression of several pluripotent stem cell markers, and (ii) to evaluate in vitro drug resistance modifications after specific CSC transcription factor switch-off. METHODS: In ex vivo experiments, eight formalin-fixed, paraffin-embedded ATC specimens were analyzed by reverse-transcription and real-time quantitative PCR and immunohistochemistry. In in vitro experiments using ATC SW1736 cells, the expression levels of OCT-4, NANOG, and ABCG2 and the sensitivity to either cisplatin or doxorubicin were evaluated after silencing. RESULTS: OCT-4, KLF4, and SOX2 transcription factors and C-KIT and THY-1 stem surface antigens showed variable up-regulation in all ATC cases. The SW1736 cell line was characterized by a high percentage of stem population (10.4±2.1% of cells were aldehyde dehydrogenase positive) and high expression of several CSC markers (SOX2, OCT4, NANOG, C-MYC, and SSEA4). SOX2 silencing down-regulated OCT-4, NANOG, and ABCG2. SOX2 silencing sensitized SW1736 cells, causing a significant cell death increase (1.8-fold) in comparison to control cells with 10 μM cisplatin (93.9±3.4% vs. 52.6±9.4%, p<0.01) and 2.7 fold with 0.5 μM doxorubicin (45.8±9.9% vs. 17.1±3.4% p<0.01). ABCG2 silencing caused increased cell death with both cisplatin (74.9±1.4%) and doxorubicin treatment (74.1±0.1%) vs. no-target-treated cells (respectively, 45.8±1.0% and 48.6±1.0%, p<0.001). CONCLUSIONS: The characterization of CSCs in ATC through the analysis of multiple pluripotent stem cell markers might be useful in identifying cells with a stem-like phenotype capable of resisting conventional chemotherapy. In addition, our data demonstrate that SOX2 switch-off through ABCG2 transporter down-regulation has a major role in overcoming CSC chemotherapy resistance.
BACKGROUND:Anaplastic thyroid carcinoma (ATC) is a rare and aggressive endocrine tumor with highly undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in ATC. The objectives of this study were (i) to characterize CSCs from ex vivo ATC specimens by investigating the expression of several pluripotent stem cell markers, and (ii) to evaluate in vitro drug resistance modifications after specific CSC transcription factor switch-off. METHODS: In ex vivo experiments, eight formalin-fixed, paraffin-embedded ATC specimens were analyzed by reverse-transcription and real-time quantitative PCR and immunohistochemistry. In in vitro experiments using ATC SW1736 cells, the expression levels of OCT-4, NANOG, and ABCG2 and the sensitivity to either cisplatin or doxorubicin were evaluated after silencing. RESULTS:OCT-4, KLF4, and SOX2 transcription factors and C-KIT and THY-1 stem surface antigens showed variable up-regulation in all ATC cases. The SW1736 cell line was characterized by a high percentage of stem population (10.4±2.1% of cells were aldehyde dehydrogenase positive) and high expression of several CSC markers (SOX2, OCT4, NANOG, C-MYC, and SSEA4). SOX2 silencing down-regulated OCT-4, NANOG, and ABCG2. SOX2 silencing sensitized SW1736 cells, causing a significant cell death increase (1.8-fold) in comparison to control cells with 10 μM cisplatin (93.9±3.4% vs. 52.6±9.4%, p<0.01) and 2.7 fold with 0.5 μM doxorubicin (45.8±9.9% vs. 17.1±3.4% p<0.01). ABCG2 silencing caused increased cell death with both cisplatin (74.9±1.4%) and doxorubicin treatment (74.1±0.1%) vs. no-target-treated cells (respectively, 45.8±1.0% and 48.6±1.0%, p<0.001). CONCLUSIONS: The characterization of CSCs in ATC through the analysis of multiple pluripotent stem cell markers might be useful in identifying cells with a stem-like phenotype capable of resisting conventional chemotherapy. In addition, our data demonstrate that SOX2 switch-off through ABCG2 transporter down-regulation has a major role in overcoming CSC chemotherapy resistance.
Authors: A O Güre; E Stockert; M J Scanlan; R S Keresztes; D Jäger; N K Altorki; L J Old; Y T Chen Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205
Authors: Isabel Taubert; Rainer Saffrich; Abraham Zepeda-Moreno; Isabelle Hellwig; Volker Eckstein; Thomas Bruckner; Anthony D Ho; Patrick Wuchter Journal: Cytotherapy Date: 2010-11-15 Impact factor: 5.414
Authors: Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich Journal: Cancer Res Date: 2011-04-15 Impact factor: 12.701
Authors: Ilona Kryczek; Suling Liu; Michael Roh; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Mousumi Banerjee; Yujun Mao; Jan Kotarski; Max S Wicha; Rebecca Liu; Weiping Zou Journal: Int J Cancer Date: 2011-04-08 Impact factor: 7.396
Authors: F Lin; P Lin; D Zhao; Y Chen; L Xiao; W Qin; D Li; H Chen; B Zhao; H Zou; X Zheng; X Yu Journal: Cell Prolif Date: 2012-04-02 Impact factor: 6.831
Authors: Marta M Alonso; Ricardo Diez-Valle; Lorea Manterola; Angel Rubio; Dan Liu; Nahir Cortes-Santiago; Leire Urquiza; Patricia Jauregi; Adolfo Lopez de Munain; Nicolás Sampron; Ander Aramburu; Sonia Tejada-Solís; Carmen Vicente; María D Odero; Eva Bandrés; Jesús García-Foncillas; Miguel A Idoate; Frederick F Lang; Juan Fueyo; Candelaria Gomez-Manzano Journal: PLoS One Date: 2011-11-01 Impact factor: 3.240
Authors: Ying C Henderson; Soon-Hyun Ahn; Junsun Ryu; Yunyun Chen; Michelle D Williams; Adel K El-Naggar; Mihai Gagea; Rebecca E Schweppe; Bryan R Haugen; Stephen Y Lai; Gary L Clayman Journal: J Clin Endocrinol Metab Date: 2014-11-26 Impact factor: 5.958
Authors: Irem Dogan; Shigeru Kawabata; Emily Bergbower; Joell J Gills; Abdullah Ekmekci; Willie Wilson; Charles M Rudin; Phillip A Dennis Journal: Lung Cancer Date: 2014-03-29 Impact factor: 5.705
Authors: P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré Journal: Clin Transl Oncol Date: 2016-04-05 Impact factor: 3.405